Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Self-Care Devices May See Extension After EU Commission Admits MDR ‘Inconsistencies’

Executive Summary

Self-care medical devices may be included in the four-year “grace period” following implementation of the new EU Medical Device Regulation as part of an incoming corrigendum to the law, a spokesperson for the European Commission suggested at a recent AESGP meeting.

You may also be interested in...



Self-Care Medical Devices One Step Closer To Four-Year MDR Extension

Members of the European Parliament will soon decide whether to grant self-care medical devices such as nasal sprays and throat lozenges the same four-year extension as high-risk devices under the new EU Medical Devices Regulation implementation rules. 

Commission Looks Set To Expand MDR Extension So Notified Bodies Can Focus On High-Risk Devices

It looks, at long last, as if the European Commission may be making an important concession that could ease the pressure on the medical device sector as it implements the new EU Medical Device Regulation. The concession would allow more time to focus on higher-risk devices.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Topics

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel